Artivion, Inc. (NYSE:AORT) CFO Lance A. Berry Sells 3,259 Shares

Artivion, Inc. (NYSE:AORT) CFO Lance A. Berry sold 3,259 shares of the stock in a transaction on Monday, February 24th. The stock was sold at an average price of $27.31, for a total value of $89,003.29. Following the sale, the chief financial officer now directly owns 75,805 shares of the company’s stock, valued at approximately $2,070,234.55. This represents a 4.12 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Artivion Trading Down 0.2 %

AORT opened at $25.38 on Friday. Artivion, Inc. has a 12-month low of $18.38 and a 12-month high of $32.33. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.88 and a quick ratio of 1.33. The stock has a market capitalization of $1.06 billion, a PE ratio of -1,268.85 and a beta of 1.75. The firm’s fifty day moving average price is $29.63 and its 200 day moving average price is $27.81.

Artivion (NYSE:AORT) last issued its earnings results on Monday, February 24th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.12 by ($0.51). Artivion had a negative net margin of 0.22% and a positive return on equity of 5.15%. The company had revenue of $97.31 million during the quarter, compared to analyst estimates of $100.82 million. As a group, research analysts expect that Artivion, Inc. will post 0.37 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of AORT. Squarepoint Ops LLC increased its holdings in shares of Artivion by 30.8% in the 4th quarter. Squarepoint Ops LLC now owns 35,707 shares of the company’s stock valued at $1,021,000 after acquiring an additional 8,404 shares during the last quarter. Tidal Investments LLC increased its stake in Artivion by 14.5% during the fourth quarter. Tidal Investments LLC now owns 179,806 shares of the company’s stock valued at $5,141,000 after purchasing an additional 22,804 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new stake in Artivion during the fourth quarter valued at $64,000. Point72 Asset Management L.P. acquired a new stake in shares of Artivion during the fourth quarter worth $5,573,000. Finally, ProShare Advisors LLC lifted its position in shares of Artivion by 44.7% in the 4th quarter. ProShare Advisors LLC now owns 11,924 shares of the company’s stock worth $341,000 after buying an additional 3,683 shares during the last quarter. Institutional investors own 86.37% of the company’s stock.

Wall Street Analysts Forecast Growth

AORT has been the topic of several research reports. Stifel Nicolaus lowered their target price on Artivion from $33.00 to $30.00 and set a “buy” rating on the stock in a report on Tuesday. Oppenheimer upped their price objective on Artivion from $30.00 to $32.00 and gave the stock an “outperform” rating in a report on Friday, November 8th. JMP Securities restated a “market outperform” rating and issued a $33.00 price target on shares of Artivion in a report on Tuesday, December 10th. Finally, Needham & Company LLC cut their price objective on Artivion from $34.00 to $32.00 and set a “buy” rating on the stock in a research report on Tuesday. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $31.40.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.